← back to search

Christian D. Fankhauser

Lucerne University of Applied Sciences and Arts · CH
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Testicular diseases and treatments, Prostate Cancer Diagnosis and Treatment, Prostate Cancer Treatment and Research, and Bladder and Urothelial Cancer Treatments.
h-index
33
citations
5,436
works
340
NIH funding
primary concept
Medicine
email

Recent publications

Testicular Germ Cell Tumors
JAMA 2025cited by 57position: middledoi
The current landscape of single-port robotic surgery in urology
Nature Reviews Urology 2025cited by 21position: middledoi
GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment
PLoS ONE 2025cited by 18position: middledoi
Treatment strategies in human papillomavirus-related advanced penile cancer
Nature Reviews Urology 2025cited by 13position: middledoi
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding
British Journal of Urology 2024cited by 0position: lastdoi
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy—A Multicenter Study
European Urology 2023cited by 37position: middledoi
Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging–targeted Biopsy: A Study That Challenges the Dogma
The Journal of Urology 2023cited by 21position: middledoi
Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study
European Urology Open Science 2022cited by 27position: middledoi
A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer
European Journal of Cancer 2022cited by 15position: firstdoi
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics 2022cited by 4position: middledoi
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium
Journal of Clinical Oncology 2021cited by 229position: middledoi
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
Journal of Clinical Oncology 2021cited by 165position: middledoi
Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up
Minerva Urology and Nephrology 2021cited by 15position: middledoi
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)
World Journal of Urology 2021cited by 7position: middledoi
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
European Urology 2019cited by 237position: middledoi
High‐throughput proteomic analysis of <scp>FFPE</scp> tissue samples facilitates tumor stratification
Molecular Oncology 2019cited by 170position: middledoi
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Journal of Clinical Oncology 2019cited by 29position: middledoi
Automated Gleason grading of prostate cancer tissue microarrays via deep learning
Scientific Reports 2018cited by 429position: middledoi
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers
Life Science Alliance 2018cited by 59position: middledoi
Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Journal of Internal Medicine 2018cited by 30position: middledoi
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Cancer Cell 2016cited by 286position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter J. Wild · Goethe University Frankfurt3 papers (2016–2018) · 3 papers (2021–2025)Juan Gómez Rivas · Università Campus Bio-Medico3 papers (2021–2025)Qing Zhong · Apple (Israel)2 papers (2016–2018)Ruedi Aebersold · Ludwig-Maximilians-Universität München2 papers (2016–2018)Thomas Hermanns · University of Tübingen2 papers (2018–2018) · 2 papers (2021–2022) · 2 papers (2021–2022)Tiannan Guo · Westlake University2 papers (2016–2018)Ulrich Wagner · University of Zurich2 papers (2016–2018) · 2 papers (2016–2018)Giorgio Gandaglia · Vita-Salute San Raffaele University2 papers (2023–2025) · 2 papers (2018–2018) · 1 papers (2025–2025)Marcus Hentrich · BMW (Germany)1 papers (2019–2019) · 1 papers (2022–2022) · 1 papers (2022–2022)Derya Tilki · Koç University1 papers (2023–2023) · 1 papers (2021–2021)Alberto Briganti · Collaborative Group (United States)1 papers (2021–2021)